Enhancing Cancer Therapeutics: Harnessing Nanoplatforms for Mitochondria-Targeted Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 10 January 2025 | Viewed by 1002
Special Issue Editors
Interests: nanomedicines; biomaterials; drug delivery
Special Issues, Collections and Topics in MDPI journals
Interests: nanomaterials; mitochondria; cancer; diabetes; drug delivery
Special Issue Information
Dear Colleagues,
Mitochondria, the powerhouse of the cell, play a crucial role in cellular energy production and regulation of apoptosis. Targeting mitochondria has emerged as a promising strategy in cancer therapy due to the altered metabolism and mitochondrial dysfunction observed in cancer cells. Nanomedicine offers exciting opportunities in delivering therapeutic agents specifically to mitochondria, thereby enhancing efficacy and reducing off-target effects. This rapidly evolving field of nanomedicine holds great potential for revolutionizing cancer treatment by providing targeted therapies with improved selectivity and precision.
This Special Issue welcomes manuscripts focusing on the following themes:
- Design and synthesis of mitochondria-targeting nanocarriers for cancer therapy;
- Mitochondrial-specific drug delivery systems for overcoming multidrug resistance in cancer;
- Therapeutic strategies utilizing nanomedicine to modulate mitochondrial dynamics and functions in cancer cells;
- Mitochondrial imaging techniques using nanoprobes for cancer diagnosis and treatment monitoring;
- Mitochondria-targeted nanomedicine for combination therapies in cancer treatment;
- Nanotechnology-based approaches for enhancing mitochondrial photodynamic therapy in cancer;
- Safety, toxicity, and biocompatibility considerations in the development of mitochondria-targeted nanomedicine.
I look forward to receiving your contributions.
Dr. Jun Chen
Dr. Lifo Ruan
Dr. Mengxue Zhou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- mitochondria-targeting
- cancer therapy
- mitochondrial dynamics
- cancer diagnosis
- mitochondrial photodynamic therapy
